R&D Systems™ Recombinant Human Osteoprotegerin/TNFRSF11B Protein

A New and Improved rh OPG is Now Available! The new protein has ∼2 fold better activity!

Supplier:  R&D Systems™ 185OS025/CF

Catalog No. 185OS025CF

Description

Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 8-24 ng/mL.

Specifications

• Accession Number: AAB53709.1
• Formulation: Lyophilized from a 0.2 μm filtered solution in PBS.
• Molecular Weight (g/mol): M.W. (Observed): 55 kDa, reducing conditions; M.W. (theoretical): 43.5 kDa (monomer)
• Quantity: 25 μg
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.
• Endotoxin Concentration: <0.10 EU / 1 μg of the protein by the LAL method.
• Conjugate: Unconjugated
• Reconstitution: Reconstitute at 100 μg/mL in sterile PBS.
• Protein: Osteoprotegerin/TNFRSF11B

• For Use With (Application): Bioactivity
• Gene ID (Entrez): 4982
• Name: Osteoprotegerin/TNFRSF11B
• Source: Mouse myeloma cell line, NS0-derived human Osteoprotegerin/TNFRSF11B protein Glu22-Leu401
• Structural Form: Disulfide-linked homodimer
• Gene Symbol: TNFRSF11B
• Recombinant: Recombinant
• Purity or Quality Grade: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.